5EDF36F3-D370-4907-BDA1-8D5FD2B80513
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 30.650459921156372
- age_years
- 57
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.564
- MYC_TARGETS_V1+0.545
- G2M_CHECKPOINT+0.540
- E2F_TARGETS+0.503
- UNFOLDED_PROTEIN_RESPONSE+0.374
- DNA_REPAIR+0.363
- MITOTIC_SPINDLE+0.361
- PROTEIN_SECRETION+0.301
- NOTCH_SIGNALING+0.294
- MTORC1_SIGNALING+0.281
Top 10 suppressed
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.359
- KRAS_SIGNALING_DN-0.341
- MYOGENESIS-0.313
- COAGULATION-0.307
- ALLOGRAFT_REJECTION-0.261
- INFLAMMATORY_RESPONSE-0.254
- APICAL_SURFACE-0.193
- ESTROGEN_RESPONSE_LATE-0.193
- BILE_ACID_METABOLISM-0.152
- INTERFERON_GAMMA_RESPONSE-0.149
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 86379365-5FD2-4655-8B3C-B8E0EE25EE92 | — | — | 0.930 |
| 2 | A5D67B9F-5558-48FC-81A3-642D1903DA1F | — | — | 0.930 |
| 3 | 293E6D35-8392-4C44-BC18-F917989516B0 | — | — | 0.926 |
| 4 | 46BEFC7F-2F51-4331-BA86-9823EC5781B3 | — | — | 0.914 |
| 5 | SRR934777 | — | — | 0.913 |
| 6 | E79FE058-F03E-45F3-A939-356B0427E1B7 | — | — | 0.904 |
| 7 | 7A392761-6834-4B60-A49A-99D0D2AEC612 | — | — | 0.903 |
| 8 | SRR934748 | — | — | 0.901 |
| 9 | A85A0E3A-2CB9-40EB-80E9-125EC137151B | — | — | 0.898 |
| 10 | 8BC036E8-0EA0-4346-A551-2A5F8975FEAB | — | — | 0.897 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 26 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.564 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.545 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.540 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.503 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.374 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.363 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.361 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.301 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.294 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.281 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.272 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.251 | Cobimetinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.235 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.222 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.186 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.180 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.147 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.142 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.107 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.072 | Inavolisib | — uncovered |